, a bio/informatics shared resource is still "open for business" - Visit the CDS website


  1. RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library. Guo Y, Zhao S, Sheng Q, Guo M, Lehmann B, Pietenpol J, Samuels DC, Shyr Y (2015) Biomed Res Int : 862130
    › Primary publication · 26543871 (PubMed) · PMC4620295 (PubMed Central)
  2. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM (2015) Cancer Discov 5(11): 1155-63
    › Primary publication · 26286086 (PubMed) · PMC4631701 (PubMed Central)
  3. Clinical implications of molecular heterogeneity in triple negative breast cancer. Lehmann BD, Pietenpol JA (2015) Breast : S36-40
    › Primary publication · 26253813 (PubMed) · PMC4641762 (PubMed Central)
  4. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D (2015) PLoS One 10(5): e0125482
    › Primary publication · 25965342 (PubMed) · PMC4428765 (PubMed Central)
  5. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D (2015) Oncotarget 6(25): 21353-68
    › Primary publication · 25972361 (PubMed) · PMC4673270 (PubMed Central)
  6. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL (2014) Breast Cancer Res 16(4): R69
    › Primary publication · 24985072 (PubMed) · PMC4095685 (PubMed Central)
  7. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA (2014) Breast Cancer Res 16(4): 406
    › Primary publication · 25103565 (PubMed) · PMC4187324 (PubMed Central)
  8. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  9. Multi-perspective quality control of Illumina exome sequencing data using QC3. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, Shyr Y (2014) Genomics 103(5-6): 323-8
    › Primary publication · 24703969 (PubMed) · PMC5755963 (PubMed Central)
  10. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
    › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)